In addition, approximately 10% of GIST patients have no mutation in either KIT or PDGFRA, and these tumors are called wild-type GISTs and have an approximately 0% to 45% likelihood of a response to imatinib [8, 23]. This evidence concerns the gene PDGFRA and gastrointestinal stromal tumor.